M12 muscle-homing peptide – Other Categories

Gene therapy is potentially an ideal treatment for muscle tissue myopathies but targeting remains an issue. The large volume of muscle in the body versus the requirement for tissue-specificity is of particular concern. This heptapeptide has been shown to preferentially bind myofibers and thus can be used to study targeting of peptide/gene- delivery to muscle tissue. Research into gene therapy of Duchenne muscular dystrophy (DMD) and Spinal muscular atrophy (SMA) has been of particular interest with muscle targeting peptides.- This product has been shown to orientate to muscle and heart tissue and when conjugated to a phosphorodiamidate morpholino oligomer (PMO)-increases dystrophin expression by 25%. This product already shows ideal placement to continue cardiac research to overcome some of these issues.